Exploratory Trial of Topical Imiquimod in Conjunction with Pembrolizumab for Patients with Unresectable Cutaneous Metastatic Melanoma
By
Joseph B. Parker
Richard W. Joseph
Vera J. Suman
Yiyi Yan
Ruqin Chen
June 10, 2026
Clinical Scorecard: Exploratory Trial of Topical Imiquimod in Conjunction with Pembrolizumab for Patients with Unresectable Cutaneous Metastatic Melanoma
At a Glance
Category Detail
Condition Unresectable cutaneous metastatic melanoma Key Mechanisms Combination of topical imiquimod (TLR 7 agonist) with pembrolizumab (PD-1 inhibitor) to enhance immune response. Target Population Patients with unresectable melanoma with cutaneous metastases. Care Setting Single-center, open-label, non-randomized interventional study.
Key Highlights
Objective response rate (ORR) of 57.1% with 42.9% achieving complete response. Median treatment exposure was 8 cycles. 7-month progression-free survival (PFS) rate was 57.1%. Toxicities were mostly grade 1, with fatigue and anemia being the most common. Combination therapy demonstrated promising antitumor activity. Guideline-Based Recommendations
Diagnosis
Diagnosis of cutaneous metastatic melanoma based on clinical evaluation and imaging. Management
Combination of topical imiquimod with pembrolizumab for unresectable cutaneous metastases. Monitoring & Follow-up
Monitor for objective response rate and progression-free survival. Risks
Potential for grade 1 toxicities, primarily fatigue and anemia. Patient & Prescribing Data
Seven patients enrolled, predominantly male and non-Hispanic White.
Topical imiquimod applied Monday–Friday each cycle alongside pembrolizumab IV every 21 days.
Clinical Best Practices
Consider local immune modulation strategies in conjunction with systemic therapies for cutaneous melanoma. Evaluate patient response using RECIST v1.1 criteria. Related Resources & Content
